According to an editorial, precision medicine in general and precision psychiatry in particular have been much hyped areas of promise, but so far, they have failed to deliver meaningful benefits to routine clinical care outside of niche areas in disciplines like oncology. It notes that this trial failed to deliver the promise that a biomarker-guided therapy would have an efficacy advantage and also failed to support the post hoc finding of a previous trial. It concludes that the promise of precision psychiatry, that it would be possible to improve clinical outcomes by selecting treatments tailored to an individual’s neurobiology, psychology, or sociology, remains an attractive yet elusive goal.